<DOC>
	<DOC>NCT02130401</DOC>
	<brief_summary>This is a pilot study with a single active treatment arm. The study is designed to assess the efficacy of a portable, non-invasive neuromodulation system for the treatment of Type 2 Diabetes. In particular, the primary outcome measure is a reduction in A1c.</brief_summary>
	<brief_title>Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion Criteria A subject is eligible for the study if all of the following criteria are met: Provide written informed consent prior to enrollment. Is male or female between 1870 years old. Has been diagnosed with type II diabetes for greater than 12 months. Is currently either using lifestyle modification or taking one or two of the following oral antihyperglycemic agents and has been on stable doses for 90 days prior to screening: metformin DPP4 inhibitors (sitagliptin, saxagliptin, alogliptin, linaglyptin) Pioglitazone GLP1 agonist (exenatide, liraglutide, exenatide LAR) SGLT2 Inhibitors (dapaglifozin, canagliflozin) Has an A l c between 7.5 9.0% based upon point of care testing performed at visit 1. Currently performs selfmonitoring blood glucose checks at least 3 times per week. Able to adhere to protocol requirements. Exclusion Criteria A subject will be excluded if any of the following criteria are met: Has Type 1 Diabetes or Gestational Diabetes. Is pregnant or planning to become pregnant during the course of the study. Current use OR use in the past 6 months of sulfonylureas. Current use OR use in the past 6 months of insulin History of cardiovascular disease or cerebrovascular disease. Any planned surgery during the course of the study. Current continuous renal replacement therapy. Current oral or injectable steroid use or use within the previous 3 months. Previous or current treatment with deep brain stimulation. Any previous known disease, injury, or surgical intervention involving the brain or central nervous system. Moderate or greater hearing loss. Presence of a cochlear implant. Diagnosed vestibular dysfunction. Eye surgery within the previous three months. Any history of previous ear surgery. Active ear infections or a perforated tympanic membrane. Presence of a serious or unstable medical or psychological condition which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>neuromodulation</keyword>
	<keyword>caloric vestibular stimulation</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>